Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.

Highlights: [•] Humanized MAb is effective for yellow fever (YF) immunotherapy in a hamster model. [•] Treatment with 380 or 38μg MAb 24h prior to YFV challenge improves survival. [•] MAb given up to 3days post-challenge results in significant survival rates. [•] MAb therapeutic efficacy is improved in an immunocompetent animal model. [ABSTRACT FROM AUTHOR]